Samrat Pharmachem (BSE: SAMRATPH) is loss-making over the last 12 months, losing ₹2.21 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹254.80, 14% below its 52-week high. Sales fell 2.3% a year over 3 years. Debt is 0.16× equity. It is a small-cap company with a market cap of ₹79 Cr, ranked 60th of 76 Chemicals companies by market cap; the shares fell 8.9% over the past year.
- ₹267.05
- ₹267.05
- ₹248.00
- ₹260.00
- 1.8K
Health check
- ReturnsIn line
−8.9% over a year, better than 4 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthShrinking
Sales −2.3% a year over 3 years.
- ProfitabilityNegative
ROCE -3.7% vs peer median 10.6%.
- Balance sheetStretched
Debt 0.16× equity, operating profit doesn’t cover interest, Piotroski 3 of 9.
- Red flags3 to check
Loss-making over the last twelve months.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹79 Cr
- Small cap
- P/E
- n/a
- Industry 18.2
- Price to book
- 1.15
- Peers 2.62
- Dividend yield
- 0.00%
- ROE
- −4.7%
- Peers 11.7%
- ROCE
- −3.7%
- Peers 10.6%
- Debt to equity
- 0.16
- Debt ₹11 Cr
- EPS (TTM)
- −₹7.14
- OPM (TTM)
- −0.5%
- Net margin −0.8%
- Sales growth
- +5.4%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 0.27
- EV/EBITDA −60.7
Strengths and risks
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −4.7%.
- Interest coverage of only −4.7×.
About Samrat Pharmachem
Samrat Pharmachem Limited manufactures and sells pharmaceutical chemicals in India. It offers 3-5-di iodosalicylic acid, ammonium iodide, cadmium iodide, calcium iodate, clioquinol, copper iodide, ethyl iodide, ethylenediamine dihydroiodide, hydroiodic acid, iodine, iodine monochloride, iodoquinol, methyl iodide, n-iodo succinimide, periodic acid, potassium iodate and iodide, potassium metaper iodate, povidone iodine, sodium iodate and iodide, and sodium…
- Headquarters
- Mumbai
- Employees
- 30
- Sector
- Basic Materials
- ISIN
- INE103E01016
- Website
- samratpharmachem.com
Price range
- Avg volume (3M)
- 1.7K
- 1-year return
- minus 8.9%
- From 52-week high
- minus 14.5%
Peers · Chemicals
| Company | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| NAVINFLUORNavin Fluorine International | 9,010.00 | plus 1.87% | 46,250 | 50.8 | 42.7 | 18.7% | 34.3% | 0.28 | 16.5% | plus 46.1% |
| DEEPAKNTRDeepak Nitrite | 1,533.60 | minus 0.67% | 20,917 | 19.7 | 22.3 | 10.8% | 18.0% | 0.27 | −0.5% | minus 11.9% |
| TATACHEMTata Chemicals | 607.45 | minus 1.36% | 15,475 | – | 12.4 | −3.0% | 12.2% | 0.36 | −4.8% | minus 31.0% |
| DEEPAKFERTDeepak Fertilisers & Petrochemicals Corp. | 1,155.30 | minus 0.69% | 14,599 | 14.8 | 11.5 | 11.2% | 17.6% | 0.76 | 2.6% | minus 22.7% |
| RPELRaghav Productivity Enhancers | 1,780.80 | plus 0.95% | 8,178 | 116.0 | 107.1 | – | 29.9% | 0.02 | 23.5% | plus 95.4% |
| GNFCGujarat Narmada Valley Fertilizers and Chemicals | 451.80 | minus 1.87% | 6,639 | 6.3 | 5.4 | 10.4% | 14.8% | 0.01 | −8.8% | minus 7.2% |
| ACIArchean Chemical Industries | 416.40 | minus 1.95% | 5,141 | 51.3 | 23.2 | 7.7% | 20.0% | 0.28 | −9.2% | minus 34.6% |
| SAMRATPHSamrat Pharmachem | 254.80 | minus 2.00% | 79 | – | – | −3.7% | −0.5% | 0.16 | −2.3% | minus 8.9% |
| Median of 7 peers | – | −0.69% | 14,599 | 35.2 | 22.3 | 10.6% | 18.0% | 0.28 | −0.5% | −11.9% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 75.7 | 78.9 | 63.4 | 71.8 | 79.8 | |
| 75.5 | 79.2 | 64.1 | 73 | 78.9 | |
| 0.1 | −0.4 | −0.7 | −1.2 | 0.9 | |
| 0.2% | −0.5% | −1.0% | −1.7% | 1.1% | |
| 0.7 | 0 | 0.4 | −0.3 | 1 | |
| 0.4 | 0.3 | 0.1 | 0.1 | 0.1 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |
| 0.2 | −0.7 | −0.6 | −1.9 | 1.6 | |
| 210.2% | 21.5% | 19.0% | −8.7% | 44.7% | |
| −0.2 | −0.6 | −0.5 | −2 | 0.9 | |
| -0.74 | -1.90 | -1.49 | -6.59 | 2.84 |
Profit & loss
- Sales CAGR 3Y
- −2.3%
- ROE
- −4.7%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 311 | 282 | 286 | 290 | |
| – | minus 9.4% | +1.5% | +1.4% | |
| 287 | 279 | 275 | 292 | |
| 24 | 2.5 | 10.4 | −2 | |
| 7.7% | 0.9% | 3.6% | −0.7% | |
| 0.1 | 0.2 | 0.3 | −0.1 | |
| 0.9 | 0.6 | 0.5 | 0.4 | |
| 0.6 | 0.6 | 0.7 | 0.7 | |
| 0 | 1 | 0.3 | 0.3 | |
| 22.5 | 2.5 | 9.9 | −3 | |
| 26.2% | 14.2% | 28.1% | −11.1% | |
| 16.6 | 2.2 | 7.1 | −3.3 | |
| – | minus 87.0% | +228.9% | minus 146.6% | |
| 53.83 | 7.00 | 23.02 | -10.72 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 3.1 | 3.1 | 3.1 | 3.1 | |
| 60.1 | 61.9 | 68.7 | 65.1 | |
| 18.7 | 8.5 | 9.9 | 10.7 | |
| 34.8 | 48.3 | 39.8 | 45.5 | |
| 117 | 122 | 121 | 124 | |
| 10.7 | 10.7 | 10.5 | 12.8 | |
| – | – | – | 1.1 | |
| 5.9 | 7 | 6.9 | 7 | |
| 11.9 | 9.7 | 0.4 | 6.3 | |
| 88.1 | 94.4 | 104 | 97.3 | |
| 117 | 122 | 121 | 124 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −9.4 | 9.4 | −10.1 | 8.9 | |
| −3 | −0.4 | −0 | −2.6 | |
| 9.6 | −11.2 | 0.5 | −0.5 | |
| −2.8 | −2.2 | −9.6 | 5.8 | |
| −1.5 | −0.7 | −0.5 | −3.1 | |
| −10.9 | 8.7 | −10.6 | 5.8 | |
| −0.3 | −0.3 | −0.3 | −0.3 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.